Meet the Research Team that Broke the Therapeutic Ceiling in IBD 

Updated on June 18, 2024
AD 4nXe9DmNNlRixoT9F0 32GTzQf85N5PDJ JnO67 vzML7U VybJu1HJApS4TxMCLR13qUTlt8g7tDoJg3UR0F OTxk6l9udABAURhNx8fabLqjKuxy7a DtgVKuSAglaMGWUvOPaKgNGJ4eq5Kh1f X

Integrative herbal medicine has significantly evolved and is now recognized for its effectiveness in treating various illnesses. Evinature, a pioneering healthcare startup, is at the forefront of this transformation, by providing evidence-based, natural remedies that have now entered standard clinical care, both improving patient outcomes and promoting further accessibility to patients worldwide.    

Evinature has dedicated itself to creating a model in which thoroughly studied, effective, and safe natural medicine can be delivered directly to patients as fast as possible, driven by the belief that healthcare should be universally accessible. As part of this mission, Evinature provides accurate medical assessments and affordable treatments to all through a transparent, community-focused approach: develop, test, prove, and give back. This ethos has allowed Evinature to combat the stigma often associated with natural medicine, demonstrating that if treatments are scientifically validated as effective and safe, they will be embraced by the medical industry. 

Evinature is led by Co-Founders Prof. Shomron Ben-Horin, M.D., and Apan Amos Damri, and, Nir Salomon, who all recently attended the Digestive Disease Week Conference held in Washington, D.C., from May 18-21, 2024. This conference, a premier gathering for professionals in gastroenterology, hepatology, GI endoscopy, and gastrointestinal surgery, provided the platform for Evinature to present its latest groundbreaking research.

DDW 2024 Presentation: DivertX for PDS

During the conference, the team showcased their Abstract Poster of the Phase 1 trial of CoptisCurcumin (DivertX) for Post-Diverticulitis Syndrome (PDS). PDS is characterized by persistent low-grade inflammation and digestive symptoms following an acute episode of diverticulitis. Despite its prevalence, many patients may suffer due to adequate follow-ups or comprehensive diagnosis, leading to frequent misdiagnosis of IBS. Consequently, without targeted treatment for inflammation, relapse rates of an acute episode can soar to as high as 38.2%.

Evinature’s DivertX is a revolutionary natural treatment designed specifically for the symptoms associated with PDS. This innovation fills a critical void in the care continuum for diverticulitis patients, offering a preventive strategy where none previously existed. As Salomon explained, “PDS is hugely undiagnosed and misunderstood. Post-Diverticulitis Syndrome patients suffer low-grade inflammation and symptoms long after an acute episode because there are no follow-ups or treatment plans. So many are being mistreated because they’re undiagnosed or misdiagnosed with IBS.”

Evinature’s research efforts, in collaboration with Sheba Medical Center, have led to the establishment of the first disease index to address the unmet needs in gastroenterology. “No one was paying attention to this indication until now,” Salomon shared. This index is a testament to Evinature’s dedication to improving diagnostic accuracy and patient outcomes. By facilitating proper diagnosis, follow-ups, and clinic support, Evinature ensures that patients receive comprehensive care that goes beyond mere symptom management.

The development of DivertX builds on Evinature’s previous success with The CurQD® Protocol, a first-in-class nutraceutical for inflammatory bowel disease (IBD). Salomon presented this breakthrough at the 6th IBD Innovate Conference, highlighting Evinature’s commitment to advancing natural medicine through rigorous scientific validation.


Evinature’s success is a triumph of research and innovation. In a healthcare landscape often dominated by trends and misinformation, Evinature’s approach is grounded in evidence and patient-centric values, not only providing effective treatments but also promoting a holistic model of care that integrates ongoing support. This model is particularly impactful in gastrointestinal health, where accurate diagnosis and tailored treatment plans can significantly enhance patient quality of life.

14556571 1295515490473217 259386398988773604 o

The Editorial Team at Healthcare Business Today is made up of skilled healthcare writers and experts, led by our managing editor, Daniel Casciato, who has over 25 years of experience in healthcare writing. Since 1998, we have produced compelling and informative content for numerous publications, establishing ourselves as a trusted resource for health and wellness information. We offer readers access to fresh health, medicine, science, and technology developments and the latest in patient news, emphasizing how these developments affect our lives.